Observational study of patients treated with lercanidipine in conditions of clinical practice in the Czech Republic
2014
Abstract
Lercanidipine is a calcium ion channel inhibitor that is used in the treatment of mild to moderate hypertension at dosages from 10 to 20 mg. The authors of this article summarize its use in an observational trial performed in the Czech republic in 375 patients with essential arterial hypertension.
It was demonstrated the achievement of primary endpoint, i.e. significantly decreased of blood pressure. This was accompanied by a relatively small change of heart rate and positive safety profile.